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Clinical human vaccine studies have so far failed 
to demonstrate that induction of either antibody 
or T cells in isolation confer protection against 
HIV-1  infection  or  delay  disease  progression 
(Flynn et al., 2005; Buchbinder et al., 2008). A 
clinical  trial  recently  completed  in  Thailand 
(RV-144) demonstrated partial efficacy (Rerks-
Ngarm et al., 2009). In this study, the use of an 
HIV-1 recombinant canarypox vector (ALVAC-
HIV) boosted with a bivalent glycoprotein sub-
unit vaccine (AIDSVAX B/E) was able to induce 
envelope-specific antibody and T cell responses. 
Because the correlates of protection using this 
latter  vaccine  regimen  are  not  understood,  it 
would be prudent to develop strategies to in-
crease both the humoral and cell-mediated im-
mune responses induced by HIV-1 vaccines.
Recent nonhuman primate studies suggest 
a correlation of viral load with the breadth and 
magnitude of vaccine-induced CD8 T cell re-
sponses (Liu et al., 2009; Wilson et al., 2009). 
Perhaps importantly, the breadth of the CD8 
T cell responses induced by these SIV-based vac-
cines far exceeded those elicited by any HIV-1 
vaccine tested to date (McElrath et al., 2008). 
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Retroviruses pack multiple genes into relatively small genomes by encoding several genes in 
the same genomic region with overlapping reading frames. Both sense and antisense HIV-1 
transcripts contain open reading frames for known functional proteins as well as numerous 
alternative reading frames (ARFs). At least some ARFs have the potential to encode proteins 
of unknown function, and their antigenic properties can be considered as cryptic epitopes 
(CEs). To examine the extent of active immune response to virally encoded CEs, we analyzed 
human leukocyte antigen class I–associated polymorphisms in HIV-1 gag, pol, and nef genes 
from a large cohort of South Africans with chronic infection. In all, 391 CEs and 168 
conventional epitopes were predicted, with the majority (307; 79%) of CEs derived from 
antisense transcripts. In further evaluation of CD8 T cell responses to a subset of the pre-
dicted CEs in patients with primary or chronic infection, both sense- and antisense-encoded 
CEs were immunogenic at both stages of infection. In addition, CEs often mutated during 
the first year of infection, which was consistent with immune selection for escape variants. 
These findings indicate that the HIV-1 genome might encode and deploy a large potential 
repertoire of unconventional epitopes to enhance vaccine-induced antiviral immunity.
© 2010 Bansal et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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into the natural immune response to HIV-1, could poten-
tially be used to significantly increase the breadth of a vaccine 
response.
RESULTS AND DISCUSSION
CE prediction in ARFs of HIV-1
Analysis of the six possible translational reading frames of 
HIV-1 gag, pol, and nef reveals a vast number of open reading 
frames that have the potential to encode proteins and epi-
topes (Fig. 1 and Fig. S1). To gain a more comprehensive 
understanding of CD8 T cell recognition of CEs, we deter-
mined HLA-I–associated HIV-1 polymorphisms in the main 
reading  frame  encoding  the  functional  protein  reading 
frame (RF 1) and ARFs 2–6 of the gag, pol, and nef regions 
in a large cohort of clade C–infected individuals (Matthews 
et al., 2008). The resultant polymorphisms predict amino 
acid changes that have escaped CTL pressure or reverted 
once that pressure has been lifted. This analysis made correc-
tions for viral phylogeny in addition to HLA linkage disequil-
ibrium and HIV codon variation, and the resultant HIV-1 
polymorphisms indicated potential CD8 T cell escape muta-
tions (Carlson et al., 2008). We then used the amino-acid 
regions flanking the calculated polymorphisms (27mer input 
peptide, i.e., 13 amino acids on either side of the polymor-
phism) to better predict a probable CD8 T cell epitope with 
an epitope prediction program (Epipred), as indicated by a 
posterior probability (PP) of >0.1 (Heckerman et al., 2007). 
This latter strategy recognizes that a polymorphism may be 
HLA  linked  but  represent  a  processing  or  compensatory 
mutation occurring outside of the actual epitope. For a given 
HLA–peptide pair, PP is a Bayesian measure that quantifies 
the amount of evidence (based on the HLA and amino acids 
at  various  positions  in  the  peptide)  that  the  peptide  is   
indeed an epitope presented by a given HLA. The PP is 
derived  from  a  predictive  model  trained  using  known 
Foremost among these, the recent Merck trivalent vaccine 
(Step Trial) induced a median of only three CD8 T cell epi-
tope (a median of one Gag, one Pol, and one Nef response) 
responses per vaccinee, and only 31% of vaccinees demon-
strated both CD8 and CD4 T cell responses (McElrath et al., 
2008). These studies would suggest that to be effective, at 
minimum, vaccines will need to induce a considerably greater 
number of T cell responses.
The three letter codon alphabet recognized by unique 
tRNA during protein synthesis allows for three potential 
overlapping reading frames in each direction of DNA tran-
scription. A reading frame that encodes a potential peptide 
sequence that is not part of a functional protein is called an 
alternative reading frame (ARF), and within HIV-1 there 
are many such ARFs in both the sense and the antisense di-
rections of transcription (Fig. S1). Although all functional 
HIV-1 proteins are thought to be transcribed from the pos-
itive sense DNA strand, several studies have shown that anti-
sense RNA is transcribed during HIV-1 infection and that 
translation of several ARFs occurs, with the potential to gen-
erate  immunogenic  and  antigenic  peptides  called  cryptic 
epitopes (CEs), a potential source of HLA class I (HLA-I)–
presented peptides (He et al., 2008; Seila et al., 2008). After 
transcription,  there  are  multiple  mechanisms  through 
which the RNA strand can be manipulated or otherwise 
used to generate CEs, including alternative splicing pat-
terns, ribosomal frameshifting (Weiss et al., 1987), internal 
ribosomal entry sites (McBratney et al., 1993), initiation 
codon scanthrough (Bullock et al., 1997), doublet decoding 
(Bruce et al., 1986), and initiation from non-AUG codons 
(Malarkannan et al., 1999).
CD8 T cell responses targeting CEs derived from the 
positive-strand  RNA  have  been  described  previously  for 
both SIV and HIV-1 (Cardinaud et al., 2004; Maness et al., 
2007); however, the frequency and biological significance of 
these responses are unknown. Furthermore, CD8 T cell tar-
geting of CEs derived from antisense transcription has not 
been described despite evidence that HIV-1 proteins are pro-
duced from this process (Michael et al., 1994; Ludwig et al., 
2006; Landry et al., 2007). This latter production of peptides 
could be an important source of antigenic epitopes consider-
ing the relatively large amount of CEs that can be generated 
from antisense open reading frames (Fig. S1).
In this report, we predict frequent targeting of CEs de-
rived from ARFs in chronic infection by identifying HIV-1 
polymorphisms associated with specific HLA-I alleles. The 
majority of these CE responses are predicted to occur in the 
pol region and most CEs are derived from antisense tran-
scription, possibly because of the large number of potential 
peptides synthesized from this region. Using PBMCs from 
early and chronically HIV-1–infected patients, we show that 
CD8 T cell targeting of CEs is a frequent occurrence. Finally, 
we show evidence of evolution at predicted CEs during the 
first year of HIV-1 infection. Immune targeting of protein 
products derived from antisense transcription is a previously 
unrecognized process that, in addition to providing insight 
Figure 1.  Predicting CE-specific CD8 T cells using HLA-I–associated 
HIV-1 polymorphisms. HLA-I–associated HIV-1 polymorphisms in gag, 
nef, and pol were used to predict potential CD8 T cell epitopes in all read-
ing frames. The number of predicted epitopes is compared between  
protein (sense RF 1) and the ARFs (the other five reading frames). The 
ARFs include sense ARFs 2 and 3 as well as antisense ARFs 4–6.JEM VOL. 207, January 18, 2010  53
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(79% compared with ARFs 2 and 3) were predicted to be 
targeted by CD8 T cells (Fig. 1).
Recognition of predicted CEs by HIV-1–infected patients
These data are the first to suggest that epitopes derived 
from antisense transcripts are common CD8 T cell targets 
in HIV-1 infection. Although predicting CD8 T cell epi-
topes based on HLA-I–associated HIV-1 polymorphisms is 
a validated approach (Carlson et al., 2008; Goepfert et al., 
2008), it has not been used to predict CEs. For functional 
analysis, we selected CEs that were calculated to have the 
highest chance of representing a true CD8 T cell epitope 
(Table I), i.e., predicted epitopes with a PP of >0.2 (i.e., 
those with a 20% chance of representing a true CD8 T cell 
epitope). We also excluded from consideration peptides in 
the ARF that could be associated with a mutation in RF 
1. Using these criteria, the dominance of peptides from pol 
still persisted among the 24 peptides that we selected to test 
(P = 0.02; Table I). Interestingly, the majority of the peptides 
HLA-restricted epitopes. In addition, the predictive model 
uses a prior probability of 0.1. Consequently, our use of a PP 
threshold of 0.1 amounts to selecting putative epitopes that 
have net positive evidence for being actual epitopes. This 
analysis predicted 391 CEs in the five combined ARFs for 
gag, pol, and nef genes compared with 168 conventional 
epitopes encoded in RF 1 (Fig. 1). For each gene, the 
number  of  predicted  CEs  outnumbered  the  number  of 
conventional epitopes, but this was most prominent for the 
pol region (209 vs. 30, respectively). Despite the fact that 
antisense transcription has been demonstrated to occur for 
many cellular and viral genes including HIV-1 (Michael et al., 
1994; He et al., 2008), previous studies have only analyzed 
responses to CEs derived in the forward reading frames 
(Cardinaud et al., 2004). Therefore, we determined the 
proportion  of  CEs  predicted  to  be  targeted  by  CD8   
T cells in the forward (ARFs 2 and 3) and reverse (ARFs 
4–6) reading frames. Interestingly, for gag, pol, and nef, a 
greater percentage of the peptides encoded for ARFs 4–6 
Table I.  CEs predicted based on HLA-I–associated HIV-1 polymorphisms
ARF Protein HLA Best epitopea Peptide PPb PHIc CHIc
%
2 pol B*3910 ---ELKTFGRF+--- EF8 30 1 (0) 0 (0)
3 gag A*01 ---SSHANvKRY--- SY9* 54 7 (0) 7 (0)
3 pol B*15 ---YRYSISRtY--- YY9 40 1 (0) 3 (0)
3 pol C*07 ---YRfSISRAY--- YY9* 20 13 (1) 17 (1)
3 pol C*07 ---NLWKKGYRf--- NF9 30 13 (0) 17 (2)
4 pol A*3001 ---FcFPPWYYL--- FL9 51 2 (0) 9 (0)
4 pol A*34 ---NIPCFSYf---- NF8* 26 2 (0) 4 (0)
4 pol B*15 ---LCFYVATgY--- LY9 31 1 (0) 3 (2)
4 pol B*35 -–+SPAILFWQL--- SL9 30 4 (0) 7 (0)
4 pol B*42 ---LPKSDLREv--- LV9 51 1 (0) 2 (0)
5 pol A*0205 ---SVnCFTSLV--- SV9* 35 14 (0) 20 (0)
5 gag A*3001 -+-CLQPSDVSK--- CK9* 29 2 (1) 9 (0)
5 pol A*3002 -+-AYFPVFRFL--- AL9* 28 2 (0) 9 (1)
5 pol A*33 ---TGHLPANF+--- TF8 26 1 (0) 4 (0)
5 nef A*6801 ---SLTaGHPTM--- SM9 30 1 (0) 8 (0)
5 gag B*08 ---FPHFQQPf---- FF8* 36 5 (1) 9 (0)
5 pol B*35 ---IPNAYcESV--- IV9 42 4 (0) 7 (1)
5 pol B*5802 ---ASFIWPPTF-+- AF9 40 4 (1) 5 (1)
5 gag C*0801 ---NVAPGPNAL--+ NL9* 58 1 (0) 2 (0)
5 pol C*0804 --+FPTNFCISL--- FL9 27 1 (0) 2 (0)
5 pol C*18 ---DPTYkSSI--- DI8* 26 0 (0) 1 (0)
6 pol A*0205 --+SLLVHVWLPL-- SL10 29 14 (1) 20 (1)
6 pol A*29 ---NMHPPHPVL--+ NL9 69 4 (0) 1(1)
6 pol B*5802 ---LPSPFLHkL--- LL9 28 4 (1) 5 (2)
CD8 T cell epitopes were predicted by Epipred. Bolded and underlined amino acids were recognized in primary (PHI) and chronic (CHI) HIV-1 infections, respectively. Lowercase 
letters and plus signs represent HLA-associated HIV-1 polymorphisms within and outside the predicted epitope, respectively. The asterisks indicate evidence for reversion in 
the predicted epitope.
aPredicted epitope from an input 27mer sequence.
bPP indicates the percent probability that the predicted epitope represents a real epitope.
cNumber of patients with the allele that were tested (number of responses).54 Antisense HIV-1–specific CD8 T cell epitopes | Bansal et al.
patient (Fig. 2 B), and CD8 T cell responses to at least one 
epitope were detected in 21% of patients with primary and 
15% with chronic infection (Fig. 2 B). The actual number 
of CE responses is likely to be higher because we evaluated 
only a small subset of predicted CEs, and we tested clade 
C–predicted CEs in the context of clade B infection. Fur-
ther evidence attesting to the specificity of these CE re-
sponses is that none of the predicted CEs appeared similar 
to known HIV-1 epitopes restricted by the indicated HLAs. 
Additionally, we scanned each of these predicted CEs in the 
BLAST search engine (http://www.ncbi.nlm.nih.gov/blast) 
and did not find any sequence match to known human patho-
gens in the database.
The CEs tested in this paper were predominantly 9–
10mers derived from antisense ARFs (Table I) and were 
predicted to stimulate CD8 T cells. To confirm that CE 
responses were derived from antisense ARFs and are recog-
nized by CD8 T cells, we stimulated PBMCs from 14 HIV-
1–infected individuals (5 chronic and 9 primary) directly ex 
vivo with selected CEs in a 6-h intracellular cytokine stain-
ing (ICS) assay and stained the cells with antibodies specific 
for CD3, CD8, IFN-, TNF, IL-2, perforin, and CD107. 
A representative figure demonstrates that the A02-SL10 CE 
induces production of IFN-, TNF, and perforin by CD8 
T cells (Fig. 3 A). In a subset of individuals, we used a 
peptide-based cultured assay to quantify the responses elic-
ited to CEs and found that low frequency antigen-specific 
cells expanded 5–10-fold over a 10-d culture of PBMCs 
stimulated with the cognate peptide (Fig. 3 B). This mod-
est expansion in precursor frequency was also observed in 
other  HIV-1–infected  patients  (unpublished  data)  and  is 
consistent with the generally poor proliferative responses 
seen in patients with chronic progressive HIV-1 infection 
(Migueles et al., 2002). We next compared the ex vivo 
functional profile of the CE-specific CD8 T cells to those 
were derived from ARFs 4–6 (products of antisense tran-
scription and translation).
The predicted CEs (Table I) were tested using PBMCs 
from 41 patients with chronic and 24 patients with primary 
HIV-1 subtype B infection in an overnight IFN- ELISPOT 
assay (Bansal et al., 2007). We tested the reactivity of CEs in 
a subtype B cohort, reasoning that HLA-I–restricted CEs 
would be similar across subtypes (including subtype C), as 
has been demonstrated with conventional epitopes (Kawashima 
et al., 2009). CE-specific responses were detected in HIV- 
1–infected individuals during both primary and chronic 
infection (Fig. 2 A). In contrast, we saw below threshold 
responses to these CEs among the 15 seronegative (SN) 
controls tested. Similar to those observed for conventional epi-
topes (Altfeld et al., 2001), the magnitude and breadth of CE 
responses, as measured by IFN-, was significantly higher 
in patients with chronic compared with primary infection 
(P < 0.0001), suggesting that CE responses are progres-
sively targeted with chronic infection. Overall, 48% of the 
tested CEs demonstrated a positive response in at least one 
Figure 2.  CE-specific responses are recognized by CD8 T cells in 
HIV-1 infection. (A) An IFN- ELISPOT assay using antigen-specific stim-
ulation in duplicate was used to determine the magnitude of T cell re-
sponses in primary (PHI; n = 24) and chronic (CHI; n = 41) HIV-1 subtype 
B–infected patients. These responses were compared with SN controls  
(n = 15). Each symbol represents the response magnitude to an individual 
CE. The dotted line indicates the cutoff for a positive response (>55 
SFCs/106 PBMCs), and horizontal bars represent medians. (B) The percent-
age of patients or peptides that elicited a CE-specific response are shown. 
The percent positive is shown on top of the bar.
Figure 3.  CE-specific CD8 T cells produce cytokines and effector 
molecules. (A and B) PBMCs were stained for phenotype and functionally 
characterizing CE-specific T cell responses. The production of cytokines 
(IFN-, IL-2, and TNF) and up-regulation of CD107 and perforin by antigen-
specific CD8 T cells were measured (percentages are shown). Representa-
tive data from a chronically infected patient showing CE-specific 
responses as measured ex vivo (A) and after a 10-d culture (B) are shown.JEM VOL. 207, January 18, 2010  55
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varying E/T ratios for 24 h (Fig. 4, C and D). The relative 
amount of target cell lysis was calculated by the diminution of 
intracellular p24 by the effectors when compared with infected 
targets  alone.  The  HLA-I–matched  HIV-1–infected  targets 
demonstrated significant killing of targets cells by the CE-
specific cell line when compared with the HLA-I–mismatched 
control (Fig. 4 E). This finding demonstrates that a peptide en-
coded by an HIV-1 antisense reading frame is generated in in-
fected CD4 T cells, transported to the cell surface, and presented 
to CE-specific CD8 T cells in an HLA-I–dependant manner.
To be certain that CE responses do not represent cross-
reactive responses induced by conventional HIV-1–specific 
epitopes, we determined whether an A*0205-SL10 CE-
specific cell line could recognize other known HLA-A*02– 
restricted  epitopes. As  expected,  the  CE-specific  cell  lines 
lysed targets pulsed with the A*0205-restricted CE but not 
other conventional epitopes nor another CE restricted by the 
same allele (Fig. S3 A). We also stained the CE-specific T cells 
from a 10-d culture assay with an A*0205 pentamer to fur-
ther demonstrate the specificity of CE responses (Fig. S3 B).
elicited by conventional immunodominant (ID) HIV epi-
topes in the same patient samples. The CE-specific CD8   
T cells were able to produce all of the functional molecules 
analyzed and did not differ significantly from the ID re-
sponses (Fig. S2).
Antisense reading frame–derived CEs are restricted by the 
predicted HLA-I alleles and presented by HIV-1–infected cells
To verify that CE responses were in fact restricted by the pre-
dicted HLA-I alleles, we derived two CE-specific CD8 T cell 
lines  (A*3002-AL9  and  A*0205-SL10;  Table  I)  from  two 
chronic patients that recognized epitopes derived from the pol 
antisense reading frames (ARFs 5 and 6, respectively). In a 51Cr 
release assay, each of these T cell lines lysed peptide-pulsed 
HLA-I–matched but not –mismatched targets (Fig. 4, A and B). 
Next, we infected HLA-I–matched and –mismatched acti-
vated CD4 T cells from healthy SN donors with HIV-1 NL4.3 
at a multiplicity of infection (MOI) of 0.1. 2 d later, infected 
cells  were  used  as  targets  and  co-cultured  with  either  the 
A*3002-AL9–specific or the A*0205-SL10–specific cell line at 
Figure 4.  CE-specific T cells recognize peptide-pulsed and HIV-1–infected targets. (A and B) T cell lines were derived by peptide-specific stimula-
tion followed by limiting dilution cloning. MHC restriction of the T cell lines was determined using matched (continuous lines) and mismatched (dashed 
lines) HLA-I–expressing B cell lymphoblastic cell lines as targets in a 51Cr release assay for an A*3002-restricted AL9-specific T cell line (A) and an A*0205-
restricted SL10-specific T cell line (B). The HLA-Is of the patient from whom the T cell line was derived are A*3001/A*6601, B*4201/B*5703, and Cw*1701/
Cw*1801 (A), and A*0201/A*0301, B*0702/B*5701, and Cw*0602/Cw*0702 (B). The HLA-Is of B cell lymphoblastic cell lines that are shared with the patient 
are shown inside the panel. Results are representative of three independent experiments. (C–E) CD8 T cell–depleted PBMCs from HLA-1–matched  
or –mismatched donors were activated with PHA for 2 d and infected with HIV-1 NL4.3 at an MOI of 0.1 for 2 d. The infected targets were co-cultured 
with effectors, i.e., a CE-specific line (A*3002-AL9 [C] or A*0205-SL10 [D]), at 1:10, 1:5, and 1:1 E/T ratios for 24 h. The killing of infected targets was  
measured by p24 reduction in an ICS assay. (C and D) Density plots showing the percentage of p24 staining of target cells after co-culture with the effector 
line. (E) The percentage killing of HLA-I–matched versus –mismatched targets by the A*3002–AL9 and A*0205-SL10 cell lines are shown graphically.56 Antisense HIV-1–specific CD8 T cell epitopes | Bansal et al.
topes derived from ARFs. This frameshift requirement results 
in an 10-fold decrease in Pol protein production compared 
with Gag (Gaudin et al., 2005), with a concomitant decrease 
in epitope production (Tsomides et al., 1994). Therefore, we 
speculate that CE production, which is also dependant in part 
on defective ribosomal translation, might be better able to 
compete with epitopes derived from the Pol protein.
Importantly, the CE predictions were biologically con-
firmed to be targeted by CD8 T cells in the context of pri-
mary and chronic HIV-1 infection. The functionality of these 
cells did not differ substantially when compared with those 
targeting conventional epitopes in their ability to secrete 
cytokines and synthesize perforin. CD8 T cells were shown 
to kill CE-specific targets, including those that presented epi-
topes derived from antisense transcription after HIV-1 infec-
tion. Additionally, the specificity of these cells was demonstrated 
by the fact that they could not recognize target cells pulsed 
with  HIV-1–specific  conventional  epitopes  that  were  re-
stricted by similar HLA-I alleles as the CE analyzed (Fig. S3).
Our findings demonstrate that targeting of CEs appears 
to be placing immune pressure on the virus. The fact that CEs 
were predicted based on evidence of CD8 T cell escape indi-
cates at least some level of significant antiviral immune pres-
sure. Additionally, several CEs (Table I, asterisks) were also 
predicted to revert back to consensus when transmitted to a 
host that lacks the HLA-I restricting allele. We also demon-
strate that both reversions and escape mutations of predicted 
epitopes and one biologically confirmed epitope (C*07  YY9; 
reversion) were noted during the first year after infection 
CEs evolve after primary HIV-1 infection
Perhaps the best indicator of immune potency is viral escape in 
response to immune pressure and reversion when the pressure 
no longer exists. Although we predicted the presence of CD8 
T cell targeting based on evidence of escape and reversion, 
these data were obtained cross-sectionally in a chronically in-
fected cohort and, hence, provide indirect evidence of selec-
tion. Therefore, we sought direct evidence of selection by 
determining if CEs (predicted in the chronic cohort) mutate 
during the first year of HIV-1 infection, similar to what has 
been  observed  for  conventional  epitopes  (Brumme  et  al., 
2008). In 37 epidemiologically linked transmission pairs (LTPs) 
from Zambia, we sequenced HIV-1 gag, nef, and pol at baseline 
and every 3 mo for 1 yr. We hypothesized that mutations in 
the main reading frame, especially the synonymous mutations, 
may actually reflect CD8 T cell escape mutations in CEs de-
rived from overlapping ARFs. Therefore, we analyzed the 
number  of  nonsynonymous  mutations  (those  that  result  in 
amino acid changes in the protein) as well as the number of 
synonymous mutations in the main reading frame of Gag, Pol, 
and Nef proteins that resulted in amino acid changes in one or 
more of the five ARFs during the first year of infection. This 
analysis enabled us to determine if any of the HLA-I–associated 
HIV-1 polymorphisms predicted in the chronic cohort (in all 
six reading frames) were observed to mutate in these linked re-
cipients. As expected from previous studies (Brumme et al., 
2008), several nonsynonymous mutations (RF 1) occurring in 
the Gag, Nef, and Pol proteins during the first year of infection 
matched the predicted conventional epitope escape mutations 
in the chronic South African cohort (Fig. 5). Additionally, for 
all of the antisense reading frames (ARFs 4–6, occurring within 
gag, nef, and pol), several synonymous mutations in the main 
reading frame corresponded to amino acid changes in predicted 
CEs that are likely caused by immune pressure (escape or re-
version) and not to chance alone (P < 0.01). Predicted CE 
mutations were also significantly observed in the sense reading 
frames (ARFs 2 and 3) of gag and pol (P < 0.04) but not nef. 
Similar to what has been observed previously for conventional 
epitopes (Li et al., 2007), the majority of CE changes occurring 
during the first year of infection were predicted to be rever-
sions, although some CD8 T cell escapes were also noted.
Collectively, our results support the notion that epitopes 
derived from antisense RNA transcripts frequently serve as 
CD8 T cell targets in HIV-1 infection. Indeed, 307 out of 
559 (55%) of all of the predicted CD8 T cell responses (con-
ventional and cryptic) targeted CEs that were derived from 
antisense reading frames. The highest number of predicted 
CEs is derived from antisense transcription in the pol region, 
exceeding the epitopes derived from the Pol protein and epi-
topes derived from sense RNA transcripts of either gag, pol, or 
nef (Fig. 1). The dominance of CEs from pol was confirmed 
with the IFN- ELISPOT results whereby 9 out of 11 (82%) 
of the positive epitopes were encoded in this region (Table I). 
It is interesting that a ribosomal frameshift is necessary for 
pol translation (Gaudin et al., 2005) and in that sense would 
have a similar mechanism of synthesis compared with epi-
Figure 5.  Evolution of predicted CEs after primary HIV-1 infec-
tion. Sequencing of gag, nef, and pol was performed in 37 epidemiologi-
cally linked recipients from Zambia at the time of identified infection and 
every 3 mo for the first year. The number of observed mutations during 
this time that matched the predicted HLA-I–associated HIV-1 polymor-
phisms in the chronic cohort (Fig. 1) as a percentage of the total observed 
mutations (those not predicted in the chronic cohort) is shown. The total 
number of predicted mutations is shown above each bar. Symbols next to 
the number of predicted mutations designate the reading frames where 
mutations, predicted from the chronic cohort, were not caused by chance 
alone (*, P < 0.04; †, P < 0.01; ‡, P < 0.0001).JEM VOL. 207, January 18, 2010  57
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those for HIV-1 infection. This increased breadth could be 
achieved using similar-sized vaccine inserts potentially modi-
fied to increase CE expression. Although the partial efficacy 
seen in the RV-144 study seems most likely caused by the in-
duction of HIV-1–specific antibodies (Rerks-Ngarm et al., 
2009), it is still possible that T cells played a supportive role. 
With this in mind, it is interesting to note that the ALVAC-
HIV vaccine used in RV-144 is not codon optimized (unlike 
the Merck trivalent vaccine) and could potentially induce CE 
responses. Therefore, it may be important to take into ac-
count the contribution of CE-induced responses in the over-
all CD8 T cell repertoire of future vaccine constructs.
MATERIALS AND METHODS
Calculation of HLA-I–associated HIV polymorphisms. HLA-I–associated 
HIV polymorphisms were identified as previously described (Carlson et al., 
2008). In brief, for gag, nef, and pol, a maximum likelihood phylogenetic 
tree was constructed using chronic clade C sequences (Matthews et al., 2008). 
For every HLA allele, amino acid position, and amino acid at that position, two 
generative or directed graphical models of the observed presence or absence of 
the amino acid in each sequence were created: (1) the null hypothesis, stating 
that observations are generated by the phylogenetic tree alone, and (2) the al-
ternative hypothesis, stating that additional escape or reversion takes place be-
cause of HLA pressure. The likelihood of the observations was then maximized 
over the parameters of both models using an expectation-maximization algo-
rithm, and a p-value was computed using a likelihood ratio test. To account for 
HLA linkage disequilibrium and HIV codon covariation, for each HIV amino 
acid, HLA alleles and other amino acids are iteratively added to the model of 
selection pressure using forward selection. In each step, the likelihood ratio test 
compares the model with and without the most recently added predictor. To 
account for multiple hypothesis testing, the p-values were converted to 
q-values as previously described (Storey and Tibshirani, 2003). We analyzed all 
associations with q < 0.2, corresponding to a 20% false discovery rate.
Identification of predicted epitopes. For each HLA-I–associated poly-
morphism, we constructed a consensus sequence that was consistent with 
the predicted association. For example, if the association predicted escape 
from A at position 100 in the presence of an HLA-I allele, then we com-
puted the consensus of all sequences with A at position 100. If the predicted 
association was reversion to A in the absence of an HLA-I allele, then we 
constructed the consensus sequence of all sequences without an A at posi-
tion 100. We then took the consensus sequence ± 13 amino acids from the 
association and used Epipred (Microsoft Corporation) to identify the most 
likely epitope in the candidate sequence.
Identification of mutations after HIV transmission in LTPs. Early 
and late sequences from 37 LTPs were aligned to the consensus sequence 
from the Durban cohort, which was used to identify HLA-I–associated poly-
morphisms. Each sequence was then translated into each reading frame, and 
mutations were identified and classified as HLA-I-associated or not, as previ-
ously described (Brumme et al., 2008). In brief, an observed mutation was 
classified as HLA-I–associated if it was exactly consistent with the predicted 
association from the Durban dataset. For example, if the association was es-
cape from A100 in the presence of an HLA-I allele, then the patient must 
have the HLA-I variant and we must see a mutation away from A at position 
100. If the association was reversion to A100 in the absence of the HLA-I 
allele, then the patient must not have the HLA-I allele, and we must see a 
mutation toward A. For ARFs, we removed all mutations that were nonsyn-
onymous relative to the primary reading frame.
Patient cohort for CE testing. PBMC samples from clade B HIV-1 early 
(n = 24) and chronically infected (n = 41) patients were used in this study. 
These patients were enrolled in the 1917 Clinic at the University of Birmingham 
(Fig. 5). The evidence for reversion, in particular, suggests 
that several CEs are evolutionarily conserved by the virus be-
cause of fitness constraints, a phenomenon similar to what is 
seen for some conventional HIV-1 epitopes (Goepfert et al., 
2008). A recent study also suggested that targeting CEs may 
be important by demonstrating more frequent CE responses 
in patients with well-controlled HIV-1 infection (Garrison 
et al., 2009).
Because optimal translation necessitates a variety of fac-
tors including an ATG methionine start codon, previous 
studies have evaluated ARF sequences in the forward read-
ing frame containing ATG (Cardinaud et al., 2004; Maness 
et al., 2007). In contrast, we evaluated epitopes derived from 
antisense RNA transcripts with or without an optimized 
start codon because the evidence obtained from our HLA-
I–associated  HIV-1  polymorphism  analysis  indicated  that 
these CEs indeed represent CD8 T cell targets. Notably, a 
methionine start codon is not always necessary for transla-
tion initiation, as several nonmethionine start codons have 
also been described (Malarkannan et al., 1999). It is also pos-
sible that CEs can be generated even when no known start 
codon is present because of ribosomal slippage (Maness et al., 
2010). Such alternative mechanisms of peptide synthesis may 
well result in a relatively lower epitope production; how-
ever, many of these alternatively synthesized peptides may 
nonetheless be immunogenic (Schwab et al., 2003).
Although the magnitude of IFN- CE responses was rel-
atively low when compared with CD8 T cells targeting ID 
epitopes, it is clear from previous studies that the magnitude 
of CD8 T cell response is a poor correlate of immune control 
in HIV-1 infection (Betts et al., 2001; Masemola et al., 2004). 
Escape from CD8 T cells, however, can be one indication of 
immune potency, and a recent study demonstrated escape 
from CD8 T cells of low magnitude early after primary HIV-1 
infection (Goonetilleke et al., 2009). Perhaps the best cor-
relate of immune control in chronic HIV infection is the 
breadth of CD8 T cells responding against Gag and possibly 
Pol epitopes (Kiepiela et al., 2007; Goepfert et al., 2008; 
Matthews et al., 2008). Clearly, CEs have the potential to 
contribute to an enhanced breadth of a CD8 T cell immune 
response for therapy or preventive modalities.
These results may have important implications for vaccine 
design and suggest that a significant number of new epitopes 
could be included as vaccine targets. Importantly, codon op-
timization, which was used to increase expression of HIV-1 
proteins by the Merck trivalent vaccine, results in a marked 
skewing of the translated products obtained from the ARFs, 
which may differ by as much as 80% compared with non–
codon-optimized genes (unpublished data). There are a large 
number of open reading frames (products of sense and anti-
sense transcription) that can potentially encode for additional 
CD8 T cell epitopes. In fact, for the gag, pol, and nef regions, 
an additional 5,376 CD8 T cell epitopes are potentially en-
coded by the ARF (compared with 1,785 encoded by the 
main reading frame). Therefore, targeting CEs could greatly 
increase  the  epitope  breadth  of  several  vaccines  including 58 Antisense HIV-1–specific CD8 T cell epitopes | Bansal et al.
Statistics. Analyses of variables between each group were performed using 
the nonparametric Mann-Whitney test. All analyses were performed with 
Prism software (GraphPad Software, Inc.).
Online supplemental material. Fig. S1 depicts open reading frame maps 
for gag, nef, and pol. Fig. S2 shows that CE-specific responses elicit multiple 
effector functions. Fig. S3 depicts the specificity of an SL10 CE-specific 
T cell line. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20092060/DC1.
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